Meeting
2022 ASCO Annual Meeting
Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.
Authors
Hao Liao
Peking University Cancer Hospital, Beijing, China
Hao Liao , Jianxin Zhong , Wendi Pei , Shao Bin , Xiao-ran Liu , Hope S. Rugo , Huiping Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 535)
DOI
10.1200/JCO.2022.40.16_suppl.535
Abstract #
535
Poster Bd #
307
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.
First Author: Shanshan Chen
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
Poster
2015 ASCO Annual Meeting
Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).
First Author: Nicholas Zdenkowski